Skip to content

Letrozole Stimulation vs Artificial Hormone Cycles in Endometrial Preparation for Frozen Embryo Transfer in Women with Polycystic Ovary Syndrome Undergoing IVF: A Prospective Randomized Clinical Trial

Letrozole Stimulation vs Artificial Hormone Cycles in Endometrial Preparation for Frozen Embryo Transfer in Women with Polycystic Ovary Syndrome Undergoing IVF: A Prospective Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17014124
Enrollment
Unknown
Registered
2017-12-24
Start date
2017-12-13
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome, infertility

Interventions

A:Letrozole stimulation cycles
B:Artificial hormone cycles

Sponsors

Reproductive Medicine Centre, Department of Obstetrics and Gynecology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women aged =20 and =40 years old; 2. Women who have =1 years history of infertility; 3. Women diagnosed as PCOS according to 2003 Rotterdam PCOS diagnosis criteria; 4. Women who underwent cycles < 3; 5. Women who have the indications for IVF or ICSI; 6. Women who have available high-quality embryo= 1 before FET.

Exclusion criteria

Exclusion criteria: 1. Women diagnosed as endometrial polyp, endometrial atypical hyperplasia, intrauterine adhesion, submucous myoma that can influence pregnancy; 2. Women diagnosed as moderate or severe adenomyosis; 3. Women who have ovarian tumor and/or the other tumors; 4. Women who have experienced recurrent unstable endocrine disease: thyroid disease; 5. Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy; 6. Women who have obvious hydrosalpinx hydronephrosis; 7. Women whose endometrial thickness = 7 mm in previous IVF and/or FET; 8. Women who had already joined in the other studies; 9. Women who are allergic to drugs and/or unable to tolerate them.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;

Secondary

MeasureTime frame
Implantation rate;On-going pregnancy rate;Early pregnancy loss rate;Ectopic pregnancy rate;

Countries

China

Contacts

Public ContactYu Li

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

liyuliyu0922@163.com+86 13660141860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026